CO2023006513A2 - Forma cristalina iii del compuesto agonista de receptor de melanocortina y método de preparación para la misma - Google Patents
Forma cristalina iii del compuesto agonista de receptor de melanocortina y método de preparación para la mismaInfo
- Publication number
- CO2023006513A2 CO2023006513A2 CONC2023/0006513A CO2023006513A CO2023006513A2 CO 2023006513 A2 CO2023006513 A2 CO 2023006513A2 CO 2023006513 A CO2023006513 A CO 2023006513A CO 2023006513 A2 CO2023006513 A2 CO 2023006513A2
- Authority
- CO
- Colombia
- Prior art keywords
- form iii
- preparation
- crystal form
- receptor agonist
- method therefor
- Prior art date
Links
- 229940117029 Melanocortin receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 239000000336 melanocortin receptor agonist Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000001757 thermogravimetry curve Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se relaciona a una forma cristalina III representada por la fórmula 1, un método para preparar la misma y una composición farmacéutica que comprende la misma. La forma cristalina III representada por la fórmula 1 de la presente invención se puede caracterizar mediante patrones XRD, perfiles DSC y/o perfiles TGA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200142398 | 2020-10-29 | ||
| PCT/KR2021/015473 WO2022092913A1 (ko) | 2020-10-29 | 2021-10-29 | 멜라노코르틴 수용체 작용제 화합물의 결정형 ⅲ 및 이의 제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023006513A2 true CO2023006513A2 (es) | 2023-07-31 |
Family
ID=81384121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0006513A CO2023006513A2 (es) | 2020-10-29 | 2023-05-17 | Forma cristalina iii del compuesto agonista de receptor de melanocortina y método de preparación para la misma |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230382895A1 (es) |
| EP (1) | EP4219474A4 (es) |
| JP (1) | JP2023548165A (es) |
| CN (1) | CN116507616A (es) |
| AU (1) | AU2021370072B2 (es) |
| CA (1) | CA3195304A1 (es) |
| CL (1) | CL2023001222A1 (es) |
| CO (1) | CO2023006513A2 (es) |
| IL (1) | IL302428A (es) |
| MX (1) | MX2023004732A (es) |
| PE (1) | PE20240366A1 (es) |
| TW (1) | TWI823169B (es) |
| WO (1) | WO2022092913A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4249483A4 (en) * | 2020-12-22 | 2024-05-15 | Lg Chemical Ltd | CRYSTALLINE FORM I OF A MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR THE PREPARATION THEREOF |
| JP2024501828A (ja) * | 2020-12-22 | 2024-01-16 | エルジー・ケム・リミテッド | メラノコルチン受容体アゴニスト化合物の結晶形ｉｉおよびその製造方法 |
| CN116635033A (zh) * | 2020-12-22 | 2023-08-22 | 株式会社Lg化学 | 黑皮质素受体激动剂化合物的结晶形式iii及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000074679A1 (en) * | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
| US7157463B2 (en) * | 2001-01-23 | 2007-01-02 | Eli Lilly And Company | Substituted piperidines/piperazines as melanocortin receptor agonists |
| AR044510A1 (es) | 2003-04-14 | 2005-09-14 | Merck & Co Inc | Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina |
| WO2005047251A1 (en) * | 2003-11-12 | 2005-05-26 | Lg Life Sciences Ltd. | Melanocortin receptor agonists |
| TWI332501B (en) | 2006-07-14 | 2010-11-01 | Lg Life Sciences Ltd | Melanocortin receptor agonists |
| UA99555C2 (en) * | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
| CA3053168A1 (en) | 2017-02-08 | 2018-08-16 | Tilray, Inc. | Methods and apparatus for low-pressure radiant energy processing of cannabis |
| PT3953327T (pt) * | 2019-11-07 | 2024-02-05 | Lg Chemical Ltd | Agonistas do recetor de melanocortina-4 |
-
2021
- 2021-10-29 TW TW110140344A patent/TWI823169B/zh active
- 2021-10-29 IL IL302428A patent/IL302428A/en unknown
- 2021-10-29 WO PCT/KR2021/015473 patent/WO2022092913A1/ko active Application Filing
- 2021-10-29 CN CN202180073237.0A patent/CN116507616A/zh active Pending
- 2021-10-29 JP JP2023526439A patent/JP2023548165A/ja active Pending
- 2021-10-29 US US18/251,129 patent/US20230382895A1/en active Pending
- 2021-10-29 CA CA3195304A patent/CA3195304A1/en active Pending
- 2021-10-29 PE PE2023001515A patent/PE20240366A1/es unknown
- 2021-10-29 MX MX2023004732A patent/MX2023004732A/es unknown
- 2021-10-29 AU AU2021370072A patent/AU2021370072B2/en active Active
- 2021-10-29 EP EP21886907.1A patent/EP4219474A4/en active Pending
-
2023
- 2023-04-27 CL CL2023001222A patent/CL2023001222A1/es unknown
- 2023-05-17 CO CONC2023/0006513A patent/CO2023006513A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL302428A (en) | 2023-06-01 |
| EP4219474A4 (en) | 2024-03-13 |
| MX2023004732A (es) | 2023-05-10 |
| AU2021370072B2 (en) | 2024-02-08 |
| KR20220057472A (ko) | 2022-05-09 |
| CA3195304A1 (en) | 2022-05-05 |
| JP2023548165A (ja) | 2023-11-15 |
| WO2022092913A1 (ko) | 2022-05-05 |
| EP4219474A1 (en) | 2023-08-02 |
| AU2021370072A1 (en) | 2023-06-01 |
| CN116507616A (zh) | 2023-07-28 |
| TW202225161A (zh) | 2022-07-01 |
| US20230382895A1 (en) | 2023-11-30 |
| PE20240366A1 (es) | 2024-03-04 |
| CL2023001222A1 (es) | 2023-11-03 |
| TWI823169B (zh) | 2023-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023006521A2 (es) | Forma cristalina iv del compuesto agonista de receptor de melanocortina y método de preparación para la misma | |
| CO2023006513A2 (es) | Forma cristalina iii del compuesto agonista de receptor de melanocortina y método de preparación para la misma | |
| CO2023006515A2 (es) | Forma cristalina i del compuesto agonista de receptor de melanocortina y método de preparación para la misma | |
| CO2023006517A2 (es) | Forma cristalina ii del compuesto agonista de receptor de melanocortina y método de preparación para la misma | |
| AR065272A1 (es) | Formas cristalinas de un compuesto de tiazolidinodiona, y metodos de fabricacion de las mismas | |
| BRPI0804994A2 (pt) | forma cristalina vi de agomelatina, um processo para a sua preparação e composições farmacêuticas contendo-a | |
| UY33317A (es) | Nuevos derivados de pirazol | |
| UY32096A (es) | Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones | |
| EA201691119A1 (ru) | Производные мочевины или их фармакологически приемлемые соли | |
| BR112013030973A8 (pt) | processo para a preparação de amidas de prostaglandina | |
| AR083100A1 (es) | Monohidrato de derivados de aza-adamantano | |
| EA201990688A1 (ru) | Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение | |
| ES2531159T3 (es) | Compuestos y métodos para el tratamiento del cáncer | |
| CO2023006514A2 (es) | Agonista de receptor de melanocortina-4 amorfo | |
| MX2022009281A (es) | Inhibidores de rorgamma. | |
| UY36746A (es) | Método para la síntesis de derivados de rapamicina | |
| RU2019100065A (ru) | Кристаллы анилинпиримидинового соединения, действующего в качестве ингибитора EGFR | |
| PE20211756A1 (es) | FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß | |
| WO2020127208A8 (en) | Pharmaceutical process and intermediates | |
| AR100095A1 (es) | Formas sólidas del ácido {[(2r,3s,4r,5s)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxi-benzoico | |
| BR112023022863A2 (pt) | Forma cristalina vii do composto agonista do receptor de melanocortina e método para preparar o mesmo | |
| BR112023022334A2 (pt) | Formas cristalinas de sulfato do composto agonista do receptor de melanocortina, seus métodos de preparação, seus usos, e composições farmacêuticas compreendendo as mesmas | |
| CL2022002821A1 (es) | Compuestos de bencimidazol para el tratamiento de trastornos metabólicos | |
| BR112022001271A2 (pt) | Forma cristalina de venetoclax, processo para preparar anidrato de venetoclax cristalino, composição farmacêutica, método para tratamento de câncer, anidrato de venetoclax cristalino, e, venetoclax cristalino | |
| BR112023022532A2 (pt) | Forma cristalina do derivado de tiofeno e método de preparação do mesmo |